Venetoclax Plus Rituximab Is Superior To Bendamustine Plus Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia - Results From Pre-Planned Interim Analysis Of The Randomized Phase 3 Murano Study
BLOOD（2017）
摘要
Introduction
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要